



**Vaccines and Global Health: The Week in Review**  
**19 April 2025 :: Issue 794**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

*:: [Public Consultations/Call for Inputs/Call for Papers](#)*

## ***Milestones, Perspectives***

.....  
.....

### **Pandemic Accord**

#### **WHO Member States conclude negotiations and make significant progress on draft pandemic agreement**

*Proposal to be submitted to World Health Assembly in May for consideration*

16 April 2025 News release

Geneva, Switzerland

After more than three years of intensive negotiations, **WHO Member States took a major step forward** in efforts to make the world safer from pandemics, by forging a draft agreement for consideration at the upcoming World Health Assembly in May. The proposal aims to strengthen global collaboration on prevention, preparedness and response to future pandemic threats.

In December 2021, at the height of the COVID-19 pandemic, WHO Member States established the Intergovernmental Negotiating Body (INB) to draft and negotiate a convention, agreement or other international instrument, under the WHO Constitution, to strengthen pandemic prevention, preparedness and response.

Following 13 formal rounds of meetings, nine of which were extended, and many informal and intersessional negotiations on various aspects of the draft agreement, **the INB today finalized a proposal for the WHO Pandemic Agreement. The outcome of the INB's work will now be presented to the Seventy-eighth World Health Assembly for its consideration.**

"The nations of the world made history in Geneva today," said **Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "In reaching consensus on the Pandemic Agreement, not only did they put in place a generational accord to make the world safer, they have also demonstrated that multilateralism is alive and well, and that in our divided world, nations can still work together to find common ground, and a shared response to shared threats. I** thank WHO's Member States, and their negotiating teams, for their foresight, commitment and tireless work. We look forward to the World Health Assembly's consideration of the agreement and – we hope – its adoption."

#### **Proposals within the text developed by the INB include:**

- :: establishing a pathogen access and benefit sharing system;
- :: taking concrete measures on pandemic prevention, including through a One Health approach;
- :: building geographically diverse research and development capacities;
- :: facilitating the transfer of technology and related knowledge, skills and expertise for the production of pandemic-related health products;
- ":: mobilizing a skilled, trained and multidisciplinary national and global health emergency workforce;
- :: setting up a coordinating financial mechanism; taking concrete measures to strengthen preparedness, readiness and health system functions and resilience; and
- :: establishing a global supply chain and logistics network.

**The proposal affirms the sovereignty of countries to address public health matters within their borders, and provides that nothing in the draft agreement shall be interpreted as providing WHO any authority to direct, order, alter or prescribe national laws or policies, or mandate States to take specific actions, such as ban or accept travellers, impose vaccination mandates or therapeutic or diagnostic measures or implement lockdowns.**

Dr Tedros paid tribute to the members of the Bureau who guided the INB process: Co-Chairs Ms Precious Matsoso (South Africa) and Ambassador Anne-Claire Amprou (France), and Vice-Chairs Ambassador Tovar da Silva Nunes (Brazil), Ambassador Amr Ramadan (Egypt), Dr Viroj Tangcharoensathien (Thailand); and Ms Fleur Davies (Australia). Past members included former Co-Chair, Mr Roland Driece (the Netherlands), and former Vice-Chairs Ambassador Honsei Kozo (Japan), Mr Kazuho Taguchi (Japan), and Mr Ahmed Soliman (Egypt). The Director-General also acknowledged the constant support provided by WHO Secretariat colleagues...

...INB Co-Chair, Ambassador Amprou, said the draft agreement is a major step in strengthening the global health security architecture so people of the world would be better protected from the next pandemic..."In drafting this historic agreement, the countries of the world have demonstrated their shared commitment to preventing and protecting everyone, everywhere, from future pandemic threats," Ambassador Amprou said. **"While the commitment to prevention through the One Health approach is a major step forward in protecting populations, the response will be faster, more effective and more equitable. This is a historic agreement for health security, equity and international solidarity."**

*The INB was established in December 2021, at a special session of the World Health Assembly, bringing together Member States and relevant stakeholders, including international organizations, private sector, and civil society. At the World Health Assembly in June 2024, governments made concrete commitments to complete negotiations on a global pandemic agreement within a year. The upcoming Assembly starting 19 May 2025 will consider the proposal developed by the INB and take the final decision on whether to adopt the instrument under Article 19 of the WHO Constitution.*

.....

#### ***Editor's Note:***

We did not identify any posting of the draft "global pandemic agreement" referenced in the announcement above.

#### **A/INB/13 (Resumed session and drafting group)**

Intergovernmental Negotiating Body 7-11 April 2025

A/INB/13/2 Rev.2 - Draft programme of work

*No announcements or status update identified on the INB page.*

.....

#### **Consensus reached on WHO Pandemic Agreement – IPPS Statement**

*We welcome and celebrate the historic conclusion of negotiations on the draft WHO Pandemic Agreement.*

International Pandemic Preparedness Secretariat April 16, 2025

The agreement demonstrates a shared determination to prevent a repeat of the devastation caused by COVID-19 and to strengthen the world's collective ability to prepare for, and respond to, future pandemics. It underlines the fact that no country can face pandemics alone, and reaffirms the vital importance of international cooperation, shared responsibility, and multilateralism in preparing for and responding to global health threats. Amidst a changing global health ecosystem, this moment demonstrates what is possible when the world comes together towards a common cause.

"We commend the World Health Organization, the International Negotiating Body (INB) and the wider international community for reaching consensus on this historic agreement. We strongly support the commitments to strengthen R&D for medical countermeasures, and geographically distributed manufacturing underpinned by equity, transparency, and international collaboration which align with

the aims of the 100 Days Mission. If adopted, IPPS stands ready to support countries and our 100 Days Mission partners, and multi-sectoral stakeholders, to support the implementation of the agreement” said IPPS Co-Chairs Dr Mona Nemer, Dr Victor Dzau and Shingai Machingaidze.

.....

### **WOAH celebrates historic finalisation of the Pandemic Agreement negotiations**

*A Triumph for Global Health Security, and One Health Leadership*

*Statement* World Organisation for Animal Health [OIE]

Published on 17 April 2025

The World Organisation for Animal Health (WOAH) welcomes the landmark conclusion of the Pandemic Agreement negotiations, a decisive and historic step toward strengthening global health architecture through multilateral cooperation.

Finalised amid a backdrop of persistent and emerging health threats such as avian influenza, mpox, and Ebola, this achievement underscores the critical role of animal health in pandemic prevention and reinforces the urgent need to invest in prevention efforts at their source. This milestone also affirms WOAH’s long-standing advocacy to place **One Health at the core of global health governance**. Notably, the inclusion of provisions for zoonotic disease prevention and antimicrobial resistance marks critical progress in pandemic prevention at source...

.....

*IFPMA Statement* 16 Apr 2025

### **Conclusion of the 13th resumed meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness, and response**

On the conclusion of the 13th resumed meeting of the Intergovernmental Negotiating Body in Geneva, IFPMA delivered a statement.

.....

.....

## **Health Research/Health System Funding**

### **Annals of Internal Medicine**

April 2025 Volume 178, Issue 4

<https://www.acpjournals.org/toc/aim/current>

*Original Research*

### **Potential Clinical and Economic Impacts of Cutbacks in the President’s Emergency Plan for AIDS Relief Program in South Africa**

*A Modeling Analysis*

Aditya R. Gandhi, MD, Linda-Gail Bekker, MD, PhD, A. David Paltiel, PhD, MBA, Emily P. Hyle, MD, MSc, ... et al.

Pages:457–467

*[Excerpt from abstract]*

... *Outcome Measures:*

HIV infections, life expectancy, and lifetime costs (2023 U.S. dollars).

*Results of Base-Case Analysis:*

With current HIV programming (PEPFAR\_100%), 1 190 000 new infections are projected over 10 years; life expectancy would be 61.42 years for PWH, with lifetime costs of \$11 180 per PWH. Reduced PEPFAR funding (PEPFAR\_50% and PEPFAR\_0%) would add 286 000 and 565 000 new infections, respectively. PWH would lose 2.02 and 3.71 life-years with nominal lifetime cost reductions of \$620 per

PWH and \$1140 per PWH that would be offset at the population level by more PWH requiring treatment for infection.

*Results of Sensitivity Analysis:*

Countries with similar HIV prevalence and greater reliance on PEPFAR funding could experience disproportionately higher incremental infections and survival losses.

*Limitation:*

Budget fungibility and exact programmatic implications of reducing PEPFAR funding are unknown.

*Conclusion:*

Abrupt PEPFAR cutbacks would have immediate and long-term detrimental effects on epidemiologic and clinical HIV outcomes in South Africa.

.....  
.....

## HPV

### Tackling Human Papillomavirus (HPV) and Cervical Cancer in Eastern and Southern Africa

World Bank – *Brief*

April 15, 2025

Cervical cancer—principally caused by certain strains of the human papillomavirus (HPV)—is highly preventable. In Africa, poor access to prevention, screening and treatment contributes to 90 percent of the deaths from it. **The continent accounts for nearly a quarter of global cervical cancer deaths**, with over 72,000 women dying each year, often in the prime of their lives.

**A single dose of the HPV vaccine has been shown to offer high protection against the most dangerous HPV infections.** Governments are moving from a two-dose approach to a single-dose approach as this enables them to reach more girls. **But the vaccine is not yet rolled out in every country, and where available, access can be limited**—especially for girls who are out of school, living with HIV, or in hard-to-reach areas.

**Expanding equitable, efficient, and sustained vaccine delivery is key to protecting futures and preventing avoidable deaths.** This includes reaching the last mile through community health workers, schools, social registries, and tailored outreach strategies. For women who did not receive the vaccine as girls, cervical cancer screening and early management of pre-cancer or cancer remains critical. However, less than 6 percent of eligible women in Africa have ever been screened and most cases are detected too late for effective treatment.

**Three pillars—vaccination, screening and treatment—form the backbone of the WHO Global Elimination Strategy** which aims to eliminate cervical cancer as a public health problem by 2030.

#### ***Challenges***

- **From Fragmentation to Integration:** Adolescent health services are often siloed. Integration opens the door to coordinated delivery models, linking HPV vaccination with menstrual health, deworming, SRH counseling, and school-based programs.
- **From Hard-to-Reach to Smart Targeting:** School-based models miss many girls. Countries are looking for new ways to identify and provide vaccines to girls at the right age (9-14 years), including out-of-school girls and those living in remote or fragile areas.
- **From Hesitancy to Community Ownership:** Vaccine uptake is shaped by social norms. Trusted voices—mothers, teachers, religious leaders—can help overcome misconceptions about the HPV vaccine.

- **Simplifying for Scale:** The move to single-dose HPV schedules is a breakthrough—reducing costs, visits, and dropouts. Countries can now redesign delivery systems around efficiency and equity.
- **From Gaps to Growth in Screening:** Screening coverage is low, but task-shifting and new technologies (such as HPV DNA testing and thermal ablation) create momentum to expand access.
- **Sustainable Financing and Local Commitment:** While external support is critical, this is a moment to build domestic investment and cross-sector alignment—positioning HPV as a key gender and human capital priority.

.....  
 .....

## Featured Journal Content

### Science Translational Medicine

Volume 17| Issue 794| 16 Apr 2025

<https://www.science.org/toc/stm/current>

*Viewpoints*

#### **Vaccinology in the artificial intelligence era**

BY Gianmarco Gasperini, Norman Baylor, Steve Black, David E. Bloom, Jakob Cramer, Gaël de Lannoy, Philippe Denoel, Mark Feinberg, Thibault Helleputte, Gagandeep Kang [\[...\]](#) Rino Rappuoli

16 Apr 2025

*Abstract*

Artificial intelligence (AI) has already transformed vaccine antigen design and could transform the entire vaccinology pipeline, including immune responses and emerging infectious disease prediction, manufacturing and regulatory processes, clinical trial design and implementation, and vaccine access and equity. However, realizing the promise of AI for vaccinology requires more high-quality data.

*[Excerpt]*

CONCLUSIONS

**AI and ML are set to transform vaccinology in revolutionary ways.** The impact of these technologies will be profound, accelerating the speed of vaccine development, enhancing vaccine safety and efficacy, and refining dosing protocols. This transformation is not merely incremental; it is a major shift that will fundamentally alter how we approach vaccine development, testing, and delivery.

The potential benefits of AI and ML in vaccinology are manifold. They could reduce the cost of vaccine development and vaccination, making vaccines more affordable and accessible to populations worldwide. Furthermore, they could expand the range of pathogens addressed by vaccines, thereby broadening the scope of disease prevention. Importantly, AI and ML could reduce development time, enabling speedier responses to emerging infectious diseases. By harnessing the power of these technologies, we can address health disparities, improve health outcomes, and enhance social and economic well-being.

**However, realizing these benefits hinges on effective data collection, management, and utilization.** Data are the lifeblood of AI and ML. Large datasets, encompassing individual and population data, are essential for training AI models and generating meaningful insights. In the absence of data covering the global population, there is the risk that the existing biases generated by data collected mostly in high-income countries will be perpetuated. Interestingly, a prominent study has recently projected that, by around 2028, the typical size of a dataset used to train an AI model will reach the same size as the total estimated stock of public online text [\(23\)](#). Therefore, large language model developers might soon be running out of datasets on which to train their models [\(24\)](#).

**Furthermore, the full potential of AI and ML in vaccinology will not be realized without facilitating collaboration between AI and ML experts and vaccinologists and promoting data sharing without compromising intellectual property.** The intellectual property associated with AI and ML must be judiciously governed and regulated to generate benefits without stifling innovation. The time is ripe to develop a template for minimal and model data requirements, enabling countries to customize and realize the vaccine-related benefits of AI.

**The challenge of vaccination finance is another crucial aspect of ensuring that the benefits of AI and ML are broadly realized and accrue proportionately** to populations in both high-income countries and LMICs. Equitable distribution of the benefits of the technology will require innovative financing mechanisms and distribution strategies.

Moreover, **ensuring that actual and prospective vaccine recipients are well informed and that vaccination information is both ethically and politically sensitive are imperative.** Achieving these goals will necessitate enlightened and progressive leadership and continual training and alignment of vaccine, vaccination, and digital technology specialists.

**In conclusion, assuming that their pitfalls and dangers can be sensibly circumvented, AI and ML could usher in a golden era in the prevention of infectious and chronic diseases and the reduction of disease severity. By providing a powerful, beneficial, and continual boost to vaccine development and delivery, AI and ML can spur human progress, heralding a new era in vaccinology.**

#### *Acknowledgments*

*This Viewpoint is based on a conference held in Siena, Italy (27 to 28 June 2024), entitled AI and Digital Transformation of Vaccinology, which was part of the Palio Meeting Series organized by R.R. and GlaxoSmithKline (GSK). We thank the meeting organizers and support teams, M. Harrison (GSK), and P. Dormitzer (GSK) for valuable feedback.*

.....  
.....

## **Polio – PHEIC**

### **Polio this week – 16 April 2025**

#### ***Headlines***

*No new digest content identified.*

#### ***Summary of new polioviruses this week, cases and positive environmental isolates:***

- Afghanistan: eight WPV1-positive environmental samples
- Pakistan: 25 WPV1-positive environmental samples
- Chad: three cVDPV2 cases and three cVDPV2-positive environmental samples
- Djibouti: seven cVDPV2-positive environmental samples
- Ethiopia: eleven cVDPV2 cases
- Niger: one cVDPV2 case
- Occupied Palestinian territory: one cVDPV2-positive environmental sample
- Papua New Guinea: one cVDPV2-positive environmental sample

.....  
.....

## **mPox – PHEIC**



## [Africa CDC and WHO update mpox strategy as outbreaks persist](#)

17 April 2025 *Joint News Release*

Africa CDC and WHO have updated their joint Continental Response Plan for the mpox emergency as the disease continues to affect new areas. **The revised strategy focuses on controlling outbreaks, while expanding vaccination coverage and transitioning toward a longer-term, sustainable response...**

**Since the declaration of the emergency, both regional and global support has increased, particularly for the Democratic Republic of the Congo, the epicentre of the outbreak.**

**The Africa CDC and WHO Joint Continental Mpox Plan has guided these efforts, focusing on ten key pillars:** coordination, risk communication and community engagement, disease surveillance, laboratory capacity, clinical management, infection prevention and control, vaccination, research, logistics, and maintaining essential health services.

**Vaccination efforts are underway, with more than 650 000 doses administered in 6 countries, 90% of which have been administered in the Democratic Republic of the Congo.** Overall, over a million doses have been delivered to 10 countries, with efforts ongoing to secure additional vaccine supplies.

Diagnostic testing capacity in the Democratic Republic of the Congo has grown significantly, driven by the expansion of laboratory infrastructure - from 2 laboratories in late 2023 to 23 laboratories in 12 provinces today. With new, near-point-of-care tests currently being rolled out in the country, capacity is expected to increase even further.

**Despite this progress, major challenges remain. Ongoing conflict and insecurity in eastern Democratic Republic of the Congo, where the incidence of mpox remains high, as well as humanitarian aid cuts, continue to limit the public health response and restrict access to essential services.** Across countries and partners, over US\$ 220 million is needed to fill funding gaps for the mpox response.

**The updated Continental Response Plan calls for intensified efforts to bring outbreaks under control, while also taking concrete actions to integrate mpox into routine health services.**

**Along with the Continental Response Plan for Africa, WHO has updated the global strategic plan to curb - and where feasible, to stop - human-to-human transmission of mpox.** In the first two months of 2025, 60 countries reported mpox, with the majority of cases and deaths reported from the African continent. The joint Continental Response Plan is aligned with the global strategy.

Africa CDC and WHO continue to work closely with national governments, local communities, and partners to curb transmission, control the outbreak, and build longer-term resilience within public health systems.

.....  
.....

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*



:: Pre-Print Servers

::::::  
::::::

**WHO & Regional Offices** [to 19 Apr 2025]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

17 April 2025 *Joint News Release*

[\*\*Africa CDC and WHO update mpox strategy as outbreaks persist\*\*](#)

16 April 2025 *News release*

[\*\*WHO Member States conclude negotiations and make significant progress on draft pandemic agreement\*\*](#)

:::::

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**WHO African Region AFRO**

:: 18 April 2025

[\*\*African health experts commit to accelerate efforts to eliminate Neglected Tropical Diseases\*\*](#)

:: 17 April 2025

[\*\*Health ministers launch landmark polio vaccination campaign to protect 83 million children in Lake Chad Basin\*\*](#)

:: 14 April 2025

[\*\*New WHO report highlights progress in the fight against severe chronic diseases\*\*](#)

**WHO Region of the Americas PAHO**

:: 15 Apr 2025

[\*\*Strengthening public health capacities essential to ensure resilience and equity in the Americas says new PAHO report\*\*](#)

Washington, D.C., 15 April 2025 (PAHO) - The Pan American Health Organization (PAHO) today presented Implementation of the essential public health functions in the Americas: Evaluation and strengthening of capacities. This report highlights the urgent need to strengthen public health capacities in the institutions of the Region of the Americas to...

:: 14 Apr 2025

[\*\*New PAHO program boosts digital literacy for health care workers\*\*](#)

Washington, D.C., April 14, 2025 (PAHO)— The Pan American Health Organization (PAHO) is launching the Digital Literacy Program for Health Sector Personnel, a virtual initiative aimed at strengthening the digital skills of health workers across the Americas and supporting efforts to improve access to and quality of care through the use of emerging...

**WHO South-East Asia Region SEARO**

*No new digest content identified.*

**WHO European Region EURO**

*No new digest content identified.*

**WHO Eastern Mediterranean Region EMRO**

*No new digest content identified.*

## **WHO Western Pacific Region**

*No new digest content identified.*

.....

## **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

*No new digest content identified.*

.....

## **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

**[17 April 2025 | Avian Influenza A\(H5N1\) - Mexico](#)**

.....

## **Weekly Epidemiological Record**

Vol. 100, Nos. 15, pp. 123–130 11 April 2025

<https://www.who.int/publications/journals/weekly-epidemiological-record>

:: WHO's Health Emergencies Programme: acute emergencies monthly summary – February–March 2025

.....

## **New WHO Publications**

<https://www.who.int/publications>

*Selected*

17 April 2025

**[Clinical characterization of mpox including monitoring the use of therapeutic interventions: statistical...](#)**

16 April 2025

**[WHO Drug Information - Volume 39, No. 1](#)**

16 April 2025

**[WHO consolidated guidelines on tuberculosis: module 3: diagnosis](#)**

15 April 2025

**[TRS 1060 - 58th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations](#)**

15 April 2025

**[WHO consolidated guidelines on tuberculosis: module 4: treatment and care](#)**

14 April 2025

**[Infection prevention and control and water sanitation and hygiene in health facilities during mpox disease...](#)**

.....  
.....

## **USA – HHS, FDA, CDC+**

### ***Editor's Note:***

*We employ bolded red text below to identify observations we assess might be useful to readers.*

### **HHS**

#### News

#### **HHS Secretary Kennedy to Hold Press Conference on Latest CDC Data Showing Alarming Increase of Autism Epidemic**

April 15, 2025 *Press Release*

#### **'Autism Epidemic Runs Rampant,' New Data Shows 1 in 31 Children Afflicted**

April 15, 2025 *Press Release*

**NIH** [to 19 Apr 2025]

<http://www.nih.gov/>

#### *News Releases*

*No new digest content identified.*

### **FDA**

#### Press Announcements

#### **April 17, 2025 - FDA Commissioner Makary Announces New Policy on Individuals Serving on FDA Advisory Committees**

In keeping with U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr.'s promise to carry out the Department's work with "radical transparency" and mitigate perceived industry influence and conflicts of interests, FDA Commissioner Martin A. Makary, M.D., M.P.H., announces a policy directive that limits individuals employed at companies regulated by the U.S. Food and Drug Administration, such as pharmaceutical companies, from serving as official members on FDA advisory committees, where statutorily allowed. As part of this effort, the agency will prioritize and elevate the role of patients and caregivers, strengthening the voices of their communities.

The FDA uses its advisory committees to obtain independent expert advice and recommendations on scientific, technical, and policy decisions.

"While the FDA should be partnering with industry to ensure a user-friendly review process, the scientific evaluation of new products should be independent," said Commissioner Makary. "Industry employees are welcome to attend FDA advisory committee meetings, along with the rest of the American public, but having industry employees serve as official members of FDA advisory committee members represents a cozy relationship that is concerning to many Americans. In fact, the FDA has a history of being influenced unduly by corporate interests."

"Public trust in the healthcare-industrial complex is at an all-time low. We need to restore impeccable integrity to the process and avoid potential conflicts of interest," said Commissioner Makary.

Today's action will not preclude employees of regulated companies from attending or presenting their views at advisory committee meetings or serving as representative members of the committee when required by statute. Also, exceptions can be made in rare circumstances (i.e., when the scientific expertise in an area is only available from an employee of an FDA-regulated company) provided that the official strictly complies with the applicable ethics requirements.

By limiting employees of FDA-regulated companies from serving as officials, the FDA aims to boost public trust in its decisions and improve how its advisory committees operate.

### **FDA VRBPAC**

### Advisory Committee Calendar

***The Advisory Committee calendar does not list any future scheduled meetings of VRBPAC. One other advisory committee meeting has been added to the overall calendar in the last week.***

### **CDC/ACIP [U.S.]** [to 19 Apr 2025]

<http://www.cdc.gov/media/index.html>

*Latest News No new digest content identified.*

### **ACIP Meetings** [to 19 Apr 2025]

*Next ACIP Meetings*

:: April 15-16

[Final ACIP April 15-16, 2025 Meeting Agenda \(posted 4-11-2025\)](#)

[Draft ACIP April 15-16, 2025 Meeting Agenda \(posted 3-24-2025\)](#)

[Previous ACIP Feb. 26-28, 2025 Meeting Agenda \(rescheduled, posted 1-17-2025\)](#)

[ACIP Presentation Slides: April 15-16, 2025 Meeting](#)

[YouTube Live Stream Link 4-15-2025](#)

[YouTube Live Stream Link 4-16-2025](#)

:: June 25-26

:: October 22-23

### **National Vaccine Program**

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

***No 2025 meeting dates posted.***

### **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2025.html>

**April 17, 2025 / No. 13**

[PDF of this issue](#)

*No new digest content identified.*

.....

.....

### **Europe**

#### **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

*News*

**[Tick-borne encephalitis \(TBE\) in Europe: new maps published](#)**

15 Apr 2025

*Surveillance and monitoring*

**[Communicable disease threats report, 12 - 18 April 2025, week 16](#)**

16 Apr 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 12-18 April 2025 and includes updates on mpox and measles.

### **European Medicines Agency [EMA]**

<https://www.ema.europa.eu/en/news>  
*News & Press Releases*  
*No new digest content identified.*

.....  
.....

**Africa CDC** [to 19 Apr 2025]

<https://africacdc.org/>  
*Press Releases, Statements [Selected]*  
*Press Releases*

**[Africa CDC and WHO Update Mpox Strategy as Outbreaks Persist](#)**

Addis Ababa/Brazzaville/Geneva, 17 April 2025 | Africa Centers for Disease Control and Prevention (Africa CDC) and WHO have updated their joint Continental Response Plan for the mpox emergency as the disease continues to affect new areas. The revised strategy focuses on controlling outbreaks, while expanding vaccination coverage and transitioning toward a longer-term, sustainable response...

.....

**China CDC+**

<http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 19 Apr 2025]

<http://en.nhc.gov.cn/>  
*News*

*No new digest content identified.*

**National Medical Products Administration – PRC** [to 19 Apr 2025]

<http://english.nmpa.gov.cn/>  
*News*

*No new digest content identified.*

**China CDC**

**CCDC Weekly Reports: Current Volume (7)**

**2025-04-18 / No. 16 VECTOR-BORNE INFECTIOUS DISEASES ISSUE**

**[PDF of this issue](#)**

- Vital Surveillances: Variations in the Bacterial Ecosystems of Mosquito Populations — Haikou and Sanya Cities, Hainan Province, China, 2019
- Preplanned Studies: Dengue Fever Screening Awareness and Capacity in Healthcare Facilities — Guangzhou City, Guangdong Province, China, 2024
- Preplanned Studies: Pathogenic Bacteria Detection in Parasitic Fleas — Jiangxi Province, China, 2023
- Review: An Alarming Public Health Problem: Ticks and Tick-Borne Pathogens in Urban Recreational Parks

.....  
.....

***[Contents \[click to move among sections\]](#)***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

:: [\*Journal Watch\*](#)  
:: [\*Pre-Print Servers\*](#)

.....  
.....

## ***Organization Announcements***

**Paul G. Allen Frontiers Group** [to 19 Apr 2025]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 19 Apr 2025]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

**[Gates Foundation Statement on Scholarship Program](#)**

*Statement Apr 11, 2025*

The Gates Foundation's mission is to create a world where every person has the opportunity to live a healthy and productive life. We take our compliance obligations seriously to ensure we can operate in service of this mission. In September 2024, we began evaluating our Gates Scholarship program to ensure the program was reaching the broadest range of low-income students. It has been decided to expand eligibility to all Pell Grant-eligible students in order to achieve this goal. In the future, Gates Scholarship recipients will be selected through the expanded eligibility criteria.

**Bill & Melinda Gates Medical Research Institute** [to 19 Apr 2025]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 19 Apr 2025]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**Chan Zuckerberg Initiative** [to 19 Apr 2025]

<https://chanzuckerberg.com/newsroom/>

*Newsroom*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 19 Apr 2025]

<http://cepi.net/>

*CEPI News, Blog*

*Impact story*

**How new vaccine trials in West Africa boost global viral defences**

How haemorrhagic fever vaccine trials in West Africa boost viral defences for the world  
15 Apr 2025

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 19 Apr 2025]

<https://cioms.ch/>

*News; Publications; Events*

*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 19 Apr 2025]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**DNDI – Drugs for Neglected Diseases initiative** [to 19 Apr 2025]

<https://dndi.org/press/press-releases/>

*Press Releases*

*Press releases* 15 Apr 2025

**New treatment for cryptococcal meningitis enters Phase II trial as global HIV funding cuts threaten to cause a massive increase in advanced HIV disease**

**Duke Global Health Innovation Center** [to 19 Apr 2025]

<https://dukeghic.org/>

*News*

**Issue 12: 17 April 2025 | Mpox Transparency and Accountability for the Global Response**

April 17, 2025

Welcome to the twelfth issue of our report, "Mpox: Transparency and Accountability for the Global Response." In the wake of the U.S. health agencies' communications and foreign aid freeze...

**EDCTP** [to 19 Apr 2025]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*No new digest content identified.*

**Emory Vaccine Center** [to 19 Apr 2025]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 19 Apr 2025]



<http://www.euvaccine.eu/>

*Latest News, Events*

**[EVI joins new initiative to advance promising Hepatitis C vaccine: HCVIVA](#)**

An inactivated Hepatitis C vaccine showing promising results in preclinical trials moves closer to human trials, with a new project to establish and optimise production and manufacture of the vaccine.

16 April 2025

**Fondation Merieux** [to 19 Apr 2025]

<http://www.fondation-merieux.org/>

*News, Events*

*Événement co-organisé par la Fondation Mérieux & l'Université de Genève*

**[25ème Cours avancé de vaccinologie \(ADVAC\)](#)**

5-16 mai 2025 - Centre des Pensières, Veyrier-du-Lac (France)

**Gavi** [to 19 Apr 2025]

<https://www.gavi.org/>

*Press Releases*

*No new digest content identified.*

**GE2P2 Global Foundation** [to 19 Apr 2025]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – April 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 20 Mar 2025](#)

:: [Genomics :: Governance, Ethics, Policy, Practice – A Monthly Digest – March 2025](#)

**GHIT Fund** [to 19 Apr 2025]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 19 Apr 2025]

<https://www.theglobalfund.org/en/news/>

*News Releases*

14 April 2025

**[Global Fund to Provide US\\$5 Million in Emergency Relief to Support Earthquake Response in Myanmar](#)**

In response to the devastating earthquakes that struck central Myanmar on 28 March, the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has approved an emergency funding allocation of US\$5 million to support urgent health needs ...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 19 Apr 2025]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 19 Apr 2025]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 19 Apr 2025]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Immunome Project [nee Human Vaccines Project]** [to 19 Apr 2025]

<https://www.humanimmunomeproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 19 Apr 2025]

<https://www.iavi.org/>

*Press Releases, Features*

*Features*

**[Findings from papers in eBioMedicine advance development of IAVI's single-dose Lassa fever vaccine candidate](#)**

April 16, 2025

Nonhuman primates protected from Lassa fever; high-resolution images show how vaccine-induced antibodies bind to the viral surface.

April 16, 2025

**[IAVI at the World Vaccine Congress Washington 2025](#)**

IAVI leaders to guide urgent dialogue on R&D for vaccines and antibodies in a dynamic global health landscape.

**INSERM** [to 19 Apr 2025]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]** [to 19 Apr 2025]

<https://www.ich.org/>

*News/Pubs/Press Releases [Selective]*

17 April 2025

**[ICH Q1 Draft Guideline & Step 2 Presentation Now Available on the ICH Website](#)**

The ICH Q1 draft Guideline on "Stability Testing of Drug Substances and Drug Products" reached Step 2b of the ICH Process on 11 April 2025 and entered the public consultation period.

**ICRC** [to 19 Apr 2025]

<https://www.icrc.org/en/whats-new>

*Latest press releases and statements [Selected]*

**[ICRC outraged as premises in Gaza struck and damaged by explosive](#)**

*News release 17-04-2025*

**[Sudan: ICRC president warns of dire consequences if war in Sudan rages unabated for third year](#)**

*News release 14-04-2025*

**[The Tool on African Traditions and the Preservation of Humanity in Warfare](#)**

*Article 17-04-2025*

**[Artificial intelligence in the military domain: ICRC submits recommendations to UN Secretary-General](#)**

*Article 17-04-2025*

**IFFIm** [to 19 Apr 2025]

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 19 Apr 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press releases*

17/04/2025

**[Ecuador Oil Spill One Month On: Red Cross Distributes Over One Million Liters of Water and Calls for Increased Humanitarian Assistance](#)**

*Press release 15/04/2025*

**[Gruelling conditions in Myanmar as humanitarian needs remain high following devastating earthquake](#)**

*Press release 14/04/2025*

**[Return of Afghans from Pakistan could worsen already dire humanitarian situation](#)**

**IPPS - International Pandemic Preparedness Secretariat** [to 19 Apr 2025]

<https://ippsecretariat.org/news/>

*News*

**[Consensus reached on WHO Pandemic Agreement – IPPS Statement](#)**

April 16, 2025

*We welcome and celebrate the historic conclusion of negotiations on the draft WHO Pandemic Agreement.*

The agreement demonstrates a shared determination to prevent a repeat of the devastation caused by COVID-19 and to strengthen the world's collective ability to prepare for, and respond to, future pandemics. It underlines the fact that no country can face pandemics alone, and reaffirms the vital importance of international cooperation, shared responsibility, and multilateralism in preparing for and responding to global health threats. Amidst a changing global health ecosystem, this moment demonstrates what is possible when the world comes together towards a common cause.

"We commend the World Health Organization, the International Negotiating Body (INB) and the wider international community for reaching consensus on this historic agreement. We strongly support the commitments to strengthen R&D for medical countermeasures, and geographically distributed manufacturing underpinned by equity, transparency, and international collaboration which align with the aims of the 100 Days Mission. If adopted, IPPS stands ready to support countries and our 100 Days Mission partners, and multi-sectoral stakeholders, to support the implementation of the agreement" said IPPS Co-Chairs Dr Mona Nemer, Dr Victor Dzau and Shingai Machingaidze.

**Institut Pasteur** [to 19 Apr 2025]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 19 Apr 2025]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

*No new digest content identified.*

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

**[19th International Congress of Immunology](#)**

Vienna, August 17-22, 2025.

**IVAC** [to 19 Apr 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 19 Apr 2025]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 19 Apr 2025]

<https://centerforhealthsecurity.org/newsroom>  
*Center News [Selected]*  
*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 19 Apr 2025]

<http://www.msf.org/>  
*Latest [Selected Announcements]*  
*Conflict in Sudan*

**[Desperate situation for people fleeing Zamzam camp in Sudan](#)**

Press Release 18 Apr 2025

*Gaza-Israel war*

**[Gaza has become a "mass grave" for Palestinians and those helping them](#)**

Press Release 16 Apr 2025

*Conflict in Sudan*

**[Compounding crises after two years of war in Sudan leave millions more in need than ever](#)**

Press Release 14 Apr 2025

**National Academy of Medicine** - USA [to 19 Apr 2025]

<https://nam.edu/programs/>  
*News [Selected]*  
*No new digest content identified.*

**National Academies-Sciences-Engineering-Medicine [NASEM]**- USA [to 19 Apr 2025]

<https://www.nationalacademies.org/newsroom>  
*News*  
*No new digest content identified.*

**PATH** [to 19 Apr 2025]

<https://www.path.org/media-center/>  
*Newsroom [Selected]*  
*No new digest content identified.*

**Sabin Vaccine Institute** [to 19 Apr 2025]

<https://www.sabin.org/press/>  
*Latest News & Press Releases*  
*Press Releases*

**[Sabin Begins Marburg Vaccine Trial in U.S.](#)**

April 16, 2025

**UNAIDS** [to 19 Apr 2025]

<http://www.unaids.org/en>  
*News, Stories, Updates*  
*Press Release*

**[UNAIDS reacts to WHO Member States reaching Pandemic Agreement consensus](#)**

"...But, while the agreement supports equitable access to lifesaving vaccines, tests, and medicines, it falls short of what developing countries called for, particularly regarding obligations to transfer technology.

The Pandemic Agreement is not a panacea. If adopted by the World Health Assembly, a fairer response to future health crises will depend on member states taking concrete steps to implement the agreement. Governments will need clear implementation frameworks, including timelines for ensuring that all can benefit from affordable access to scientific innovation.

But if this text is adopted and implemented, if it is honoured in spirit as well as in letter, it can lay the foundations for a more effective and equitable response to future health crises – and ensure that the next time a pandemic threat emerges, it will be met by a global health system that is fairer, safer, and more resilient."

**UNICEF** [to 19 Apr 2025]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements [Selected]*

*Press release 17 April 2025*

**[At least one million children facing emergency levels of food insecurity in Haiti](#)**

PORT-AU-PRINCE/ NEW YORK, 17 APRIL 2025 –, Over one million children are facing critical levels of food insecurity in Haiti, UNICEF estimates. Persistent armed violence, repeated displacement, and lack of sufficient humanitarian access continue to threaten vulnerable families – while the risk of famine looms. Ove...

*Press release 15 April 2025*

**[Number of children in need of humanitarian assistance in Sudan doubles as conflict enters third year amid 'perfect storm' of threats to children](#)**

PORT SUDAN/AMMAN/NEW YORK, 15 April 2025 –, As the conflict in Sudan enters its third year, the number of children in need of humanitarian assistance has doubled, from 7.8 million at the start of 2023 to more than 15 million today. Without urgent action, Sudan's dire humanitarian crisis could tip into greater ca...

**Unitaid** [to 19 Apr 2025]

<https://unitaid.org/>

*Featured News*

*News releases*

**[South Africa and Unitaid partner to accelerate access to health innovations for HIV, tuberculosis and cervical cancer](#)**

15 April 2025

The National Department of Health of the Republic of South Africa and Unitaid signed a memorandum of understanding that reinforces their commitment to tackle HIV, tuberculosis (TB) and cervical cancer while strengthening the resilience of African health programs through regional production of health products.

The renewed partnership will focus on curbing HIV and TB through the introduction of game-changing innovative health products, such as lenacapavir, a twice-yearly injectable for HIV prevention, and shorter regimens to treat drug-resistant TB; eliminating cervical cancer by increasing access to screening and preventive treatment; and strengthening health responses by scaling up regional manufacturing of diagnostic tests and treatments...

**Vaccine Equity Cooperative [nee Initiative]** [to 19 Apr 2025]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 19 Apr 2025]

<https://www.vaccineacceptance.org/>

*News*

**Sabin Begins Marburg Vaccine Trial in U.S.**

Washington, D.C. – April 16, 2025 – The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate, administering doses to the first participants in Melbourne, Florida. This trial builds on ongoing Phase 2 testing in Kenya and Uganda, with initial findings from that research expected in the coming months...

**Vaccine Confidence Project** [to 19 Apr 2025]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 19 Apr 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 19 Apr 2025]

<https://wellcome.org/news/all>

*News. Opinion, Reports*

*Impact story*

**Ebola vaccine: transforming global health responses**

17 April 2025 4-minute read

Wellcome played a crucial role in the response to the 2014 West African Ebola epidemic. We invested over £10 million to treat, prevent and contain the disease. Now, two licensed vaccines are in use for the *Zaire ebolavirus* strain, protecting communities at risk during outbreaks.

*News*

**National data service will simplify access to health data for research**

15 April 2025 5-minute read

Wellcome is partnering with the UK Government to establish a new up to £600 million health data research service. It will simplify secure access to health data and speed up research to better understand ill health, opening opportunities to develop prevention, diagnosis and treatment tools for diseases.

**The Wistar Institute** [to 19 Apr 2025]

<https://www.wistar.org/news/press-releases>

*Press Releases*

April 14, 2025

**The Wistar Institute, The University of Leeds, and the Perelman School of Medicine Discover New ‘Molecular Glues’ as a Possible Therapeutic Approach for Autoimmune Conditions**



PHILADELPHIA — (April 9, 2025) —The Wistar Institute's Joseph Salvino, Ph.D., — in collaboration with Elton Zeqiraj, Ph.D., of The University of Leeds and Roger Greenberg, M.D., Ph.D., of The Perelman...

**World Bank** [to 19 Apr 2025]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

**Tackling Human Papillomavirus (HPV) and Cervical Cancer in Eastern and Southern Africa**

Cervical cancer—principally caused by certain strains of the human papillomavirus (HPV)—is highly preventable. In Africa, poor access to prevention, screening and treatment contributes to 90 percent of...

Date: April 15, 2025 Type: *Brief*

**WFPHA: World Federation of Public Health Associations** [to 19 Apr 2025]

<https://www.wfpha.org/>

*Blog, Events*

**Emergencies and Disasters Working Group**

Apr 15, 2025

Public Health in Emergencies and Disasters Working Group Chair Interview: Dr. Duha Shellah From conflicts to climate change, the need for resilient health systems and equitable access to care has never been more urgent.

**World Medical Association [WMA]**\_\_[to 19 Apr 2025]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

**The World Medical Association welcomes progress on the Global Pandemic Agreement**

Geneva, Switzerland, 16 April 2025 — The World Medical Association (WMA) commends the dedicated efforts of Member States of the World Health Organization over the past three years to negotiate the Global Pandemic Agreement and urges its formal adoption at the 78th World Health Assembly this May. As the global voice of the medical profession, the WMA has consistently advocated for an agreement that strengthens global solidarity, prioritises equity, formalises the One Health approach, and ensures that health systems and health personnel are protected, supported, and equipped to respond effectively to future public health emergencies.

This must include specific attention to the rights and needs of vulnerable populations, including those in fragile and underserved settings, who are often disproportionately affected during pandemics. Mental health must also be recognized as a core element of pandemic response, with sufficient resources allocated to support patients, healthcare workers, and affected communities.

"While acknowledging that the negotiation process involved necessary and sometimes uncomfortable trade-offs, the WMA believes the agreement marks a vital step forward," said Dr Ashok Philip, WMA President.

"Its adoption would set the world on a stronger trajectory to prevent future pandemics and to manage those that do occur more ethically, equitably, and effectively."

The WMA stands ready to support the implementation phase through its global medical networks, technical expertise, and sustained advocacy. Physicians and national medical associations will be essential in advancing pandemic preparedness and response, including advocating for timely access to resources, reporting health system failures and inequities, upholding scientific and ethical standards, and countering misinformation and disinformation.

We will continue to contribute to One Health collaboration, global health governance reform, and evidence-based public communication—guided by the principles of medical ethics and a shared commitment to health equity.

**World Organisation for Animal Health [OIE]** [to 19 Apr 2025]

<https://www.oie.int/>

*Press Releases, Statements*

*Statements*

**WOAH celebrates historic finalisation of the Pandemic Agreement negotiations**

*A Triumph for Global Health Security, and One Health Leadership*

Published on 17 April 2025

The World Organisation for Animal Health (WOAH) welcomes the landmark conclusion of the Pandemic Agreement negotiations, a decisive and historic step toward strengthening global health architecture through multilateral cooperation.

Finalised amid a backdrop of persistent and emerging health threats such as avian influenza, mpox, and Ebola, this achievement underscores the critical role of animal health in pandemic prevention and reinforces the urgent need to invest in prevention efforts at their source. This milestone also affirms WOA's long-standing advocacy to place **One Health at the core of global health governance**. Notably, the inclusion of provisions for zoonotic disease prevention and antimicrobial resistance marks critical progress in pandemic prevention at source...

.....  
.....

**ARM [Alliance for Regenerative Medicine]** [to 19 Apr 2025]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 19 Apr 2025]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 19 Apr 2025]

<http://www.dcvmn.org/>

*News; Upcoming events*

April 10, 2025

**Driving Predictable and Sustainable Vaccine Demand: DCVMN at the RVMC Meeting in Abu Dhabi**

**ICBA – International Council of Biotechnology Associations** [to 19 Apr 2025]

<https://internationalbiotech.org/news/>

*News*

*No new digest announcements identified.*

**IFPMA** [to 19 Apr 2025]

<https://ifpma.org/>

*News, Statements [Selected]*

*Statement 17 Apr 2025*

### **Open letter from the innovative pharmaceutical industry to G20 Ministers in support of the G20 Health Agenda**

On 17 April 2025, IFPMA and IPASA submitted an open letter to G20 Ministers in support of the advancement of the G20 Health Agenda.

*[Excerpt]*

#### **...Accelerating UHC through a PHC approach**

We are committed to progress toward UHC through innovation to achieve health equity, with three foundational elements: improving PHC, ensuring adequate financing, and focusing on multi-stakeholder partnerships. To improve PHC, the innovative pharmaceutical industry support strengthening health infrastructure to ensure that PHC facilities are well-equipped and accessible to all communities and contributes to enhancing the skills and capabilities of healthcare workers.

Moreover, industry develops and deploys new medical technologies and treatments, and works constructively with partners to help facilitate affordable access to the widest possible population. PHC frameworks should offer a wide range of services, from preventive care to treatment and rehabilitation. This holistic approach ensures seamless and coordinated health support throughout individuals' lives.

#### **We call on G20 to:**

##### **:: Prioritize life-course immunization (LCI) as a cornerstone of disease prevention.**

Robust national immunization services, across all ages, are foundational for integrated, people-centered PHC. With sustainable financing, comprehensive programmatic improvement, equitable access, and robust coverage monitoring, LCI enhances UHC, reinforces national security, and creates resilient health systems.

:: Increase and sustain support for PHC to ensure resilient health systems capable of providing essential services without financial hardship to individuals...

*Statement 16 Apr 2025*

### **Joint EUCOPE-IFPMA statement to support the adoption of the WHA Resolution on Rare Diseases**

On 16 April 2025, IFPMA and EUCOPE issued a statement supporting the World Health Assembly Resolution and Global Action Plan on Rare Diseases, in line with a call to action by a coalition of civil society organizations.

*Statement 16 Apr 2025*

### **Conclusion of the 13th resumed meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness, and response**

On the conclusion of the 13th resumed meeting of the Intergovernmental Negotiating Body in Geneva, IFPMA delivered a statement.

### **International Alliance of Patients' Organizations – IAPO [to 19 Apr 2025]**

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified.*

### **International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest announcements identified.*

**PhRMA** [to 19 Apr 2025]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*

.....

.....

## ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

### **AstraZeneca**

*Press Releases* - *No new digest announcements identified.*

### **Bavarian Nordic**

*Latest News*

April 16, 2025

[\*\*Bavarian Nordic's Chikungunya Vaccine Receives Recommendation from U.S. CDC's Advisory Committee on Immunization Practices \(ACIP\)\*\*](#)

### **Bharat Biotech**

*Press Releases* - *No new digest announcements identified.*

### **BioCubaFarma – Cuba**

*Últimas Noticias* - *No new digest announcements identified.*

### **Biological E**

*News* - *No new digest announcements identified.*

### **BioNTech**

*Press Releases* - *No new digest announcements identified.*

### **Boehringer**

*Press Releases*

[\*\*Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases\*\*](#)

15/04/2025 Ingelheim, Germany, and Boston, MA

### **CanSinoBIO**

*News* - *Website not responding at inquiry*

### **CIGB**

*Latest News* - *No new digest announcements identified.*

### **CinnaGen**

*Recent News* - *No new digest announcements identified.*

### **Clover Biopharmaceuticals – China**

*News* - *No new digest announcements identified.*

### **Curevac**

*News* - *No new digest announcements identified.*

## **Gamaleya National Center/Sputnik**

*Latest News and Events* - No new digest announcements identified [Last: 09 Nov 2020]  
*<https://sputnikvaccine.com/>* - No new digest announcements identified [Last: 31 Aug 2022]

## **GSK**

*Press releases for media*

16 April 2025

**[GSK's 5-in-1 meningococcal vaccine Penmenvy receives positive recommendation from US Advisory Committee on Immunization Practices](#)**

16 April 2025

**[Arexvy recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus \(RSV\) disease by US Advisory Committee on Immunization Practices](#)**

## **EuBiologics, S Korea**

*News* - No new digest announcements identified.

## **IMBCAMS, China**

*Home* - Website not responding at inquiry.

## **JNJ Innovative Medicine [Janssen]**

*Press Releases* - No new digest announcements identified

## **Merck**

*News releases* - No new digest announcements identified

## **Moderna**

*Press Releases* - No new digest announcements identified

## **Nanogen**

*News* - No new digest announcements identified.

## **Novartis**

*News* - No new digest announcements identified on website.

## **Novavax**

*Press Releases*

Apr 15, 2025

*COVID-19*

**[SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA](#)**

## **Pfizer**

*Recent Press Releases*

04.16.2025

**[ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease](#)**

## **R-Pharm**

<https://rpharm-us.com/index.php>

*[No news or media page identified]*

### **Sanofi Pasteur**

Press Releases - No new digest announcements identified.

### **Serum Institute**

News & Announcements - No new digest announcements identified.

### **Sinopharm/WIBPBIBP**

News - No new digest announcements identified.

### **Sinovac**

Press Releases - No new digest announcements identified.

### **SK Biosciences**

Press Releases - No new digest announcements identified.

### **Takeda**

Newsroom - No new digest announcements identified.

### **Valneva**

Press Releases

April 18, 2025

[Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers](#)

April 16, 2025

[Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®](#)

April 14, 2025

[Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country](#)

### **Vector State Research Centre of Virology and Biotechnology**

Home - [Website not responding [404 error]]

### **WestVac Biopharma**

Media - No new digest announcements identified.

### **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....  
.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 16, 2025 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

April 2025 Volume 27, Number 4: E237-301

<https://journalofethics.ama-assn.org/issue/regret-moral-psychology-surgical-professionalism>

#### ***Issue Theme: Surgical Care of Incarcerated Patients***

The United States incarcerates more people per capita than any other nation. Developing and maintaining clinically and ethically appropriate surgical care for incarcerated individuals requires clinicians, health care organizations, and governments to actively resist historically entrenched patterns of devaluing incarcerated individuals' humanity and personhood. Neglect of carceral patients' surgical care needs, in particular, remains systematized to the persistent detriment of incarcerated individuals' perioperative and surgical care, recovery, outcomes, and overall health. Carceral surgical patients' risk/benefit profiles must be contextualized at every stage of their care by their diminished legal agency, restricted liberty, and increased environmental risk for a range of abuses and trauma. Carceral surgical patients' vulnerabilities can be exacerbated by uncertainty or conflict about the scope and applicability of state authority relative to clinicians' authority, which can manifest in fraught interactions among clinicians, law enforcement and security personnel, and carceral facility employees tasked with monitoring incarcerated individuals outside carceral settings.

[Reviewed earlier]

### **American Journal of Human Genetics**

Apr 03, 2025 Volume 112 Issue 4 p725-964

<https://www.cell.com/ajhg/current>

#### ***This month in The Journal***

Alyson B. Barnes, Sara B. Cullinan

Genomic medicine has the potential to transform lives, but its integration into healthcare systems requires organization, coordination of regional and national efforts, and consistent funding. Moreover, the many different cultures and political structures, as well as health and health-care disparities, present around the world pose challenges to the adoption of a one-size-fits-all genomics program. Yet, the goals of improving health outcomes by meeting the specific needs of the community in a sustainable and equitable manner are shared by many national and international programs.



### **American Journal of Infection Control**

April 2025 Volume 53 Issue 4 p415-536

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

April 2025 Volume 68 Issue 4 p645-858

<https://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

April 2025 115(S1)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 112 (2025): Issue 4 (Apr 2025)

<https://www.ajtmh.org/view/journals/tpmd/112/4/tpmd.112.issue-4.xml>

[Reviewed earlier]

### **Annals of Internal Medicine**

April 2025 Volume 178, Issue 4

<https://www.acpjournals.org/toc/aim/current>

*Original Research*

#### **Potential Clinical and Economic Impacts of Cutbacks in the President's Emergency Plan for AIDS Relief Program in South Africa**

*A Modeling Analysis*

Aditya R. Gandhi, MD, Linda-Gail Bekker, MD, PhD, A. David Paltiel, PhD, MBA, Emily P. Hyle, MD, MSc, ... et al.

Pages:457–467

*Editorials*

#### **PEPFAR Funding Saves Lives and Money**

Sabrina A. Assoumou, MD, MPH, Seamus Vahey

Pages:592–593

Forty years ago, AIDS was a universally fatal condition (1). Although therapeutic regimens started to become available in the mid-1990s, they were complex and toxic. Over time, treatment became both highly effective and much simpler, requiring fewer pills to be taken once a day. There are now even effective regimens that require only monthly injections (2). This progress has dramatically improved the life expectancy and quality of life of persons with HIV. Looking to the future, we now have data from clinical trials demonstrating that HIV can be prevented with a twice-yearly antiviral injection (3)

### **Artificial Intelligence – An International Journal**

Volume 341 April 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/340/suppl/C>

[Reviewed earlier]

## **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 19 Apr 2025)

[No new digest content identified]

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 19 Apr 2025)

### **[Creating different global health futures: mapping the health research ecosystem and taking decolonial action](#)**

*This paper promotes reflexive consideration of health research practices using a decolonisation lens. We propose both incremental and more radical action in five domains: knowledge production, funding and programmes, dissemination, uptake, and education and training. We suggest four steps towards transformation and share a reflexive tool to operationalise these steps.*

Authors: Nadia Tagoe, Seye Abimbola, Davide Bilardi, Dorcas Kamuya, Lucy Gilson, Kui Muraya, Sassy Molyneux and Caesar Atuire

Citation: BMC Health Services Research 2025 25:565

Content type: Comment Published on: 17 April 2025

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 19 Apr 2025)

### **[Recurrent Mpox: divergent virulent clades and the urgent need for strategic measures including novel vaccine development to sustain global health security](#)**

*In August 2024, the Africa CDC and WHO declared Mpox a Public Health Emergency of Continental Security and a Public Health Emergency of International Concern, respectively, following a devastating global outbr...*

Authors: Samuel Onuzulike Ebede, Ibuchukwu Nkeonyenasoya Orabueze, Uzoamaka Charity Maduakor, Ifeyinwa Nkeiruka Nwafia and Martin Ekechukwu Ohanu

Citation: BMC Infectious Diseases 2025 25:536

Content type: Review Published on: 15 April 2025

### **[Advancing the understanding and management of Mpox: insights into epidemiology, disease pathways, prevention, and therapeutic strategies](#)**

*Mpox, previously known as monkeypox, is a zoonotic viral disease caused by the Mpox virus (MPXV), a member of the Orthopoxvirus genus. This disease is of significant concern due to its zoonotic transmission, w...*

Authors: Rima Hajjo, Osama H. Abusara, Dima A. Sabbah and Sanaa K. Bardaweel

Citation: BMC Infectious Diseases 2025 25:529

Content type: Review Published on: 15 April 2025

### **[COVID- 19 vaccine uptake and its determinants in Cameroon: a systematic review and meta-analysis \(2021–2024\)](#)**

*COVID-19 vaccination is crucial for mitigating the pandemic's impact. However, vaccine hesitancy and access challenges have hindered global vaccination efforts. This meta-analysis aimed to estimate the pooled ...*

Authors: Fabrice Zobel Lekeumo Cheuyem, Adidja Amani, Chabeja Achangwa, Brian Ngongheh Ajong, Claude Axel Minkandi, Myriam Mathilde Mbia Kouda Zeh, Larissa Linda Eyenga Ntsek, Jacques Philippes Essomba, Rudy Chiozem Jiogue, Olivier Ndagijimana, Ndzi Etienne Nchanji and Celestin Danwang  
Citation: *BMC Infectious Diseases* 2025 25:525  
Content type: Systematic Review Published on: 15 April 2025

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 19 Apr 2025)

[No new digest content identified]

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 19 Apr 2025)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 19 Apr 2025)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 19 Apr 2025)

#### **[Prevalence and determinants of vaccination intention towards routine immunizations in university students: a systematic review and meta-analysis](#)**

*It is well known that, to be effective, vaccination programs require a high and consistent population uptake. Nevertheless, vaccine coverage is often insufficient. University students occupy a unique position ...*

Authors: Ilaria Mussetto, Maria Chiara Bernucci, Anna Ewa Kaminska, Claudia Isonne, Antonio Sciurti, Giuseppe Migliara, Erika Renzi, Azzurra Massimi, Carolina Marzuillo, Corrado De Vito, Paolo Villari and Valentina Baccolini

Citation: *BMC Public Health* 2025 25:1443

Content type: Systematic Review Published on: 17 April 2025

#### **[Integrating COVID-19 vaccination into routine healthcare: a feasible model for epidemic response at mildmay hospital Uganda](#)**

*As the Coronavirus Disease 2019 (COVID-19) pandemic overwhelmed healthcare systems globally, integrating vaccination into primary health services became essential to expedite immunization efforts, especially i...*

Authors: Collins Ankunda, Sandra Chandini, Sharon Namasambi, Nantongo Irene, Lazarus Wana, Victor Nanono, Francine Louisa Musana, Joseph Mwaka, Susan Nakubulwa, Ronald Mulebeke and Yvonne Karamagi

Citation: *BMC Public Health* 2025 25:1406

Content type: Research Published on: 15 April 2025

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>  
(Accessed 19 Apr 2025)  
[No new digest content identified]

### **BMJ Evidence-Based Medicine**

April 2025 - Volume 30 - 2  
<https://ebm.bmj.com/content/30/2>  
[Reviewed earlier]

### **BMJ Global Health**

April 2025 - Volume 10 - 4  
<https://gh.bmj.com/content/10/4>  
[Reviewed earlier]

### **Bulletin of the World Health Organization**

2025 Mar 1; 103(3)  
<https://www.who.int/publications/journals/bulletin/>  
[Reviewed earlier]

### **Cell**

Apr 03, 2025 Volume 188 Issue 7 p1747-2042  
<https://www.cell.com/cell/current>  
[Reviewed earlier]

### **Child Care, Health and Development**

Volume 51, Issue 3 May 2025  
<https://onlinelibrary.wiley.com/toc/13652214/current>  
[New issue; No digest content identified]

### **Clinical Pharmacology & Therapeutics**

Volume 117, Issue 4 Pages: 859-1148 April 2025  
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>  
[Reviewed earlier]

### **Clinical Therapeutics**

April 2025 Volume 47 Issue 4 p249-336  
<http://www.clinicaltherapeutics.com/current>  
[Reviewed earlier]

### **Clinical Trials**

Volume 22 Issue 2, April 2025  
<https://journals.sagepub.com/toc/ctja/22/2>  
[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 19 Apr 2025]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 151 April 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/151/suppl/C>

[New issue; No digest content identified]

### **The CRISPR Journal**

Volume 8, Issue 2 / April 2025

<https://www.liebertpub.com/toc/crispr/8/1>

*Editorial Free*

#### **Genome Editing Headwinds: Can CRISPR Stay on Target?**

Rodolphe Barrangou

Page:73

Published Online:27 March 2025

<https://doi.org/10.1089/crispr.2025.0024>

*Perspective*

#### **Strategies for Interdisciplinary Human Gene Editing Research: Insights from a Swiss Project**

Agnes Kandlbinder, et al.

Pages:79–88

Published Online:2 April 2025

<https://doi.org/10.1089/crispr.2024.0041>

### **Current Genetic Medicine Reports**

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 41, Issue 1 2025

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

April 2025 - Volume 38 - Issue 2

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

### **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 19 Apr 2025]  
[No new digest content identified]

### **Developing World Bioethics**

Volume 25, Issue 1 Pages: 1-79 March 2025  
<https://onlinelibrary.wiley.com/toc/14718847/current>  
[Reviewed earlier]

### **Development in Practice**

Volume 34, Issue 6, 2024  
<https://www.tandfonline.com/toc/cdip20/34/6>  
[Reviewed earlier]

### **Development Policy Review**

Volume 43, Issue 3 May 2025  
<https://onlinelibrary.wiley.com/toc/14677679/current>  
[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 19 - 2025  
<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>  
[Reviewed earlier]

### **Disasters**

Volume 49, Issue 3 July 2025  
<https://onlinelibrary.wiley.com/toc/14677717/current>  
[Reviewed earlier]

### **eBioMedicine**

Volume 114 In progress (April 2025)  
<https://www.sciencedirect.com/journal/ebiomedicine/vol/113/suppl/C>  
[Reviewed earlier]

### **EMBO Reports**

Volume 26 Issue 7 7 April 2025  
<https://www.embopress.org/toc/14693178/current>  
[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 31, Number 4—April 2025  
<http://wwwnc.cdc.gov/eid/>  
[Reviewed earlier]

## **Epidemics**

Volume 50 March 2025

<https://www.sciencedirect.com/journal/epidemics/vol/50/suppl/C>

[Reviewed earlier]

## **Epidemiology and Infection**

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

## **Ethics & Human Research**

Volume 47, Issue 1 Pages: 1-45 January–February 2025

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Moral distress in clinical research • Research with incarcerated and homeless women***

[Reviewed earlier]

## **Ethics & International Affairs**

Volume 38 - Issue 4 - Winter 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

## **Ethics, Medicine and Public Health**

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

## **The European Journal of Public Health**

Volume 35, Issue 1, February 2025

<https://academic.oup.com/eurpub/issue/35/1>

[Reviewed earlier]

## **Expert Review of Vaccines**

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

## **Foreign Affairs**

January/February 2025

<https://www.foreignaffairs.com/issues/2025/104/1>

*Special Section*

***Will Trump Change the World?***

## **Forum for Development Studies**



Volume 52, 2025 - Issue 1  
<http://www.tandfonline.com/toc/sfds20/current>  
***Co-creating knowledge in development studies***  
[Reviewed earlier]

### **Frontiers in Medicine**

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>  
[Accessed 19 Apr 2025]

*Systematic Review*

Accepted on 14 Apr 2025

**[Building capacity for genomics in primary care: A scoping review of practitioner attitudes, education needs and enablers](#)**

Kate L.A. Dunlop, et al.

Frontiers in Medicine, doi 10.3389/fmed.2025.1577958

### **Gene Therapy – Nature**

Volume 32 Issue 2, March 2025

<https://www.nature.com/gt/volumes/32/issues/2>

[Reviewed earlier]

### **Genetics in Medicines**

Volume 27, Issue 4 April 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/4>

[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 19 Apr 2025]

[No new digest content identified]

### **Global Health Action**

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 19 Apr 2025]

[No new digest content identified]

### **Global Public Health**

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 19 Apr 2025]

#### **[Navigating authoritarian politics: towards reflexive framing in healthcare research](#)**

Authors: Marit Tolo Østebø, Kenneth Maes, Gabrielle Gibb and Rebecca Henderson

Content type: Research 17 April 2025

#### **[Why do International Health Regulations self-assessment capacities \(SPAR\) scores not predict COVID-19 control outcomes? – analysis of the relationship between SPAR scores and COVID-19 resilience scores in 2021](#)**

Authors: Fauzi Budi Satria and Feng-Jen Tsai

Content type: Research 15 April 2025

### **Health and Human Rights**

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>

#### ***Special Section: Distress Migration and the Right to Health***

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 20 - Issue 1 - January 2025

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[New issue; No digest content identified]

### **Health Policy and Planning**

Volume 40, Issue 3, April 2025

<https://academic.oup.com/heapol/issue/40/3>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 19 Apr 2025]

[No new digest content identified]

### **Human Gene Therapy**

Volume 36, Issue 7-8 / April 2025

<https://www.liebertpub.com/toc/hum/36/7-8>

[Reviewed earlier]

**Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 21 Issue 1, 2025

<https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList>

*Selected Content*

[Reviewed earlier]

**Immunity**

Mar 11, 2025 Volume 58 Issue 3 p515-766

<https://www.cell.com/immunity/current>

[Reviewed earlier]

**Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 19 Apr 2025]

[No new digest content identified]

**Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 19 Apr 2025]

[No new digest content identified]

**International Health**

Volume 17, Issue 2, March 2025

<https://academic.oup.com/inthealth/issue/17/2>

[Reviewed earlier]

**International Human Rights Law Review**

Volume 13 (2024): Issue 2 (Dec 2024)

<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol. 12 No. 4 (2025): April 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/123>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 54, Issue 1, February 2025  
<https://academic.oup.com/ije/issue/54/1>  
[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 18 Issue 1 2025  
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/18/iss/1>  
*Table of contents*  
[Reviewed earlier]

### **JAMA**

April 15, 2025, Vol 333, No. 15, Pages 1273-1370  
<https://jamanetwork.com/journals/jama/currentissue>  
*Viewpoint*

#### **Reflections on the Successes of Pediatric Vaccines**

Kathryn M. Edwards, MD

JAMA. 2025;333(15):1287-1288. doi:10.1001/jama.2025.0865

This Viewpoint discusses the importance of early and continued vaccine use in the US.

### **JAMA Health Forum**

April 2025, Vol 6, No. 4  
<https://jamanetwork.com/journals/jama-health-forum/issue>  
[Reviewed earlier]

### **JAMA Pediatrics**

April 2025, Vol 179, No. 4, Pages 359-482  
<https://jamanetwork.com/journals/jamapediatrics/currentissue>  
[Reviewed earlier]

### **JBI Evidence Synthesis**

April 2025 - Volume 23 - Issue 4  
<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>  
[Reviewed earlier]

### **Journal of Adolescent Health**

March 2025 Volume 76 Issue 3 p341-526  
<https://www.jahonline.org/current>  
[Reviewed earlier]

### **Journal of Artificial Intelligence Research**

Vol. 82 (2025)  
<https://www.jair.org/index.php/jair>  
*Contents*  
[New issue; No digest content identified]

### **Journal of Community Health**

Volume 50, Issue 2 April 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-2>

[Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 174 May 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/174/suppl/C>

[Reviewed earlier]

### **Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

### **Journal of Epidemiology & Community Health**

March 2025 - Volume 79 - 3

<https://jech.bmj.com/content/79/3>

[Reviewed earlier]

### **Journal of Evidence-Based Medicine**

Volume 18, Issue 1 March 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

### **Journal of Global Ethics**

Volume 20, Issue 3 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

***Special Issue: 20th Anniversary Forum***

[Reviewed earlier]

### **Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 36, Number 1, February 2025

<https://muse.jhu.edu/issue/54278>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 27, Issue 1 February 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-1>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 23, Issue 1 (2025)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of International Development**

Volume 37, Issue 2 Pages: 1-619 March 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

**Journal of Medical Ethics**

April 2025 - Volume 51 - 4

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 12, Issue 1 (2025)

<https://institutionalrepository.aah.org/jpcrr/>

[New issue; No digest content identified]

**The Journal of Pediatrics**

Volume 277 February 2025

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/277/suppl/C>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

Volume 18, 2025 Issue 1

<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>

[Reviewed earlier]

**Journal of Public Health Management & Practice**

March/April 2025 - Volume 31 - Issue 2

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 46, Issue 1 March 2025

<https://link.springer.com/journal/41271/volumes-and-issues/46-1>  
[Reviewed earlier]

### **Journal of the Royal Society – Interface**

April 2025 Volume 22 Issue 225

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

### **Journal of Travel Medicine**

Volume 32, Issue 3, April 2025

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

### **Journal of Virology**

Volume 99 • Number 2 • February 2025

<http://jvi.asm.org/content/current>

[Reviewed earlier]

### **The Lancet**

Apr 19, 2025 Volume 405 Number 10487 p1313-1438

<https://www.thelancet.com/journals/lancet/issue/current>

*Articles*

[\*\*Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial\*\*](#)

Jason S Richardson, et al. on behalf of the EBSI-CV-317-004 Study Group

[\*\*Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial\*\*](#)

Lauren C Tindale, et al. on behalf of the EBSI-CV-317-005 Study Group

*The Lancet Commissions*

[\*\*Achieving gender justice for global health equity: the \*Lancet\* Commission on gender and global health\*\*](#)

Sarah Hawkes, et al.

### **The Lancet Child & Adolescent Health**

Apr 2025 Volume 9 Number 4 p211-282, e10-e12

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

### **Lancet Digital Health**

Apr 2025 Volume 7 Number 4 e232-e294

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

**Lancet Global Health**

Apr 2025 Volume 13 Number 4 e599-e777

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Apr 2025 Volume 25 Number 4 p357-470, e191-e254

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Public Health**

Apr 2025 Volume 10 Number 4 e264-e346

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Mar 2025 Volume 13 Number 3 p189-288, e17-e19

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 29, Issue 4 April 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-4>

*Editorial*

**[The Enduring Mission of the MCH Journal: Affirming the Right To Science, Practice, and Community in Maternal and Child Health](#)**

Donna Petersen, Timothy Dye, Milton Kotelchuck

01 April 2025 Pages: 439 - 440

**Medical Decision Making (MDM)**

Volume 45 Issue 3, April 2025

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 103, Issue 1 Pages: 1-241 March 2025

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

**Molecular Therapy**

Apr 02, 2025 Volume 33 Issue 4 p1305-1860

<https://www.cell.com/molecular-therapy/current>

**[In this issue](#)**



Sickle cell disease (SCD) and  $\beta$ -thalassemia are two of the most common  $\beta$ -hemoglobinopathies, genetic diseases that affect the  $\beta$ -globin chains of hemoglobin. A single mutation in  $\beta$ -globin gene (*HBB*) causes the characteristic dysfunctional hemoglobin protein in SCD, while over 300 mutations across *HBB* cause severe anemia and reduced  $\beta$ -globin levels in  $\beta$ -thalassemia. Homology-directed repair (HDR) is a promising approach to restore *HBB* expression. However, HDR can be challenging because the insert cannot be homologous to the endogenous gene, and synonymous codon-optimized, intron-less sequences may be inadequate.

## **Nature**

Volume 640 Issue 8059, 17 April 2025

<https://www.nature.com/nature/volumes/640/issues/8059>

[New issue; No digest content identified]

## **Nature Biotechnology**

Volume 43 Issue 4, April 2025

<https://www.nature.com/nbt/volumes/43/issues/4>

*Editorial* 14 Apr 2025

### **Spotlight on cancer immunotherapies**

Advances in cancer immunotherapy have shown promising results for treatment of tumors, yet challenges related to therapeutic efficacy and manufacturing processes need to be overcome.

### **Cancer vaccines: the experts speak**

The development of therapeutic cancer vaccines has long been a promising yet challenging field of research. While early efforts were impeded by limited efficacy and immune escape, recent advances in immunotherapy, mRNA technology and tumor antigen discovery have sparked renewed interest in cancer vaccine development. What is the current state of the field, and how should we address the remaining challenges to bring therapeutic cancer vaccines to the clinic? Which modalities hold potential, and what might the future of therapeutic cancer vaccines look like?

Iris Marchal

Q&A 14 Apr 2025

### **Making cell therapy accessible: challenges and opportunities**

Despite major advances in bringing cancer cell therapies to the clinic, their widespread accessibility remains a substantial challenge. High manufacturing costs, lack of funding and varying regulatory standards have restricted patient access. As the field advances, researchers, clinicians, regulatory bodies, funding agencies and industry will need to work together to overcome these barriers. A group of experts share their insights into the most pressing challenges and promising strategies to make cell therapies more broadly accessible.

Iris Marchal

Q&A 14 Apr 2025

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 19 Apr 2025)

[Reviewed earlier]

## **Nature Genetics**

Volume 57 Issue 4, April 2025

<https://www.nature.com/ng/volumes/57/issues/4>  
[Reviewed earlier]

### **Nature Human Behaviour**

Volume 9 Issue 3, March 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/2>  
[Reviewed earlier]

### **Nature Medicine**

Volume 31 Issue 3, March 2025

<https://www.nature.com/nm/volumes/31/issues/3>  
[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 24 Issue 4, April 2025

<https://www.nature.com/nrd/volumes/24/issues/4>  
[Reviewed earlier]

### **Nature Reviews Genetics**

Volume 26 Issue 4, April 2025

<https://www.nature.com/nrg/volumes/26/issues/4>  
[Reviewed earlier]

### **Nature Reviews Immunology**

Volume 25 Issue 4, April 2025

<https://www.nature.com/nri/volumes/25/issues/4>  
[Reviewed earlier]

### **New England Journal of Medicine**

Volume 392 No. 15 April 17, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

**[Withdrawal of the United States from the WHO — How President Trump Is Weakening Public Health](#)**

G. Yamey and B.K. Titanji

### **NEJM Evidence**

Volume 4 No. 4 April 2025

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[Reviewed earlier]

### **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 19 Apr 2025]

Article 19 Apr 2025

**[Systematic review and meta-analysis of interventions to increase the uptake of vaccines recommended during pregnancy](#)**

Annette K. Regan, Honorine Uwimana, Michelle L. Giles

**Pediatrics**

Volume 155, Issue 4 April 2025

<https://publications.aap.org/pediatrics/issue/155/4>

[Reviewed earlier]

**PharmacoEconomics**

Volume 43, Issue 4 April 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-3>

[Reviewed earlier]

**PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 19 Apr 2025)

**[Vaccines work... and do not cause autism](#)**

Nonia Pariente

*Editorial* | published 18 Apr 2025 PLOS Biology

<https://doi.org/10.1371/journal.pbio.3003143>

**[Applications and status of gene drive in plants](#)**

Bruce A. Hay

*Perspective* | published 15 Apr 2025 PLOS Biology

<https://doi.org/10.1371/journal.pbio.3003148>

**PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 19 Apr 2025)

[No new digest content identified]

**PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 19 Apr 2025)

[No new digest content identified]

**PLoS Medicine**

<https://journals.plos.org/plosmedicine/>

(Accessed 19 Apr 2025)

**[CONSORT 2025 statement: Updated guideline for reporting randomised trials](#)**

Sally Hopewell, An-Wen Chan, Gary S. Collins, Asbjørn Hróbjartsson, David Moher, Kenneth F. Schulz, Ruth Tunn, Rakesh Aggarwal, Michael Berkwits, Jesse A. Berlin, Nita Bhandari, Nancy J. Butcher, Marion K. Campbell, Runcie C. W. Chidebe, Diana Elbourne, Andrew Farmer, Dean A. Fergusson, Robert M. Golub, Steven N. Goodman, Tammy C. Hoffmann, John P. A. Ioannidis, Brennan C. Kahan, Rachel L. Knowles, Sarah E. Lamb, Steff Lewis, Elizabeth Loder, Martin Offringa, Philippe Ravaud, Dawn P. Richards, Frank W. Rockhold, David L. Schrager, Nandi L. Siegried, Sophie Staniszezewska, Rod S. Taylor, Lehana Thabane, David Torgerson, Sunita Vohra, Ian R. White, Isabelle Boutron  
Guidelines and Guidance | published 14 Apr 2025 PLOS Medicine  
<https://doi.org/10.1371/journal.pmed.1004587>

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 19 Apr 2025)

[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>

[Accessed 19 Apr 2025]

#### **[The association between healthcare access and shingles vaccination among older adults in Virginia, United States](#)**

Chidozie Declan Iwu, Pramita Shrestha, Alyson J. Littman, Julia E. Hood

Research Article | published 15 Apr 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0316429>

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 19 Apr 2025]

[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States**

April 22, 2025 | vol. 122 | no. 16

<https://www.pnas.org/toc/pnas/122/16>

Research Article April 18, 2025

#### **[Evaluating interdisciplinary research: Disparate outcomes for topic and knowledge base](#)**

Sidney Xiang, et al.

##### *Significance*

Interdisciplinary research is essential to solving the world's most pressing problems, there are concerns that scientific institutions like journals select against it. Analyzing peer review data from 128,950 science and technology manuscripts, including those that were rejected, we found that higher knowledge-base interdisciplinarity (measured through references) was associated with higher acceptance rates, and higher topic interdisciplinarity (measured through title and abstract text) was associated with lower ones. Highly topic-interdisciplinary submissions did not fare worse if they also had high knowledge-base interdisciplinarity, and interdisciplinary journals were more favorable toward both types. This suggests the importance of distinguishing different dimensions of interdisciplinarity and their alignment with each other and the audience.

### **PNAS Nexus**

Volume 4, Issue 3, March 2025  
<https://academic.oup.com/pnasnexus/issue/4/3>  
[Reviewed earlier]

### **Prehospital & Disaster Medicine**

Volume 40 - Issue 1 - February 2025  
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>  
[Reviewed earlier]

### **Preventive Medicine**

Volume 192 March 2025  
<https://www.sciencedirect.com/journal/preventive-medicine/vol/192/suppl/C>  
[Reviewed earlier]

### **Proceedings of the Royal Society B**

April 2025 Volume 292 Issue 2044  
<https://royalsocietypublishing.org/toc/rspb/current>  
[Reviewed earlier]

### **Public Health**

Volume 240 Pages 1-222 (March 2025)  
<https://www.sciencedirect.com/journal/public-health/vol/240/suppl/C>  
[Reviewed earlier]

### **Public Health Ethics**

Volume 18, Issue 1, April 2025  
<http://phe.oxfordjournals.org/content/current>  
[Reviewed earlier]

### **Public Health Genomics**

2025, Vol. 28, No. 1  
<https://karger.com/phg/issue/28/1>  
[Reviewed earlier]

### **Public Health Reports**

Volume 140 Issue 1, January/February 2025  
<https://journals.sagepub.com/toc/phrg/140/1>  
[Reviewed earlier]

### **Qualitative Health Research**

Volume 35 Issue 3, March 2025  
<https://journals.sagepub.com/toc/QHR/current>  
[Reviewed earlier]

## **Research Ethics**

Volume 21 Issue 2, April 2025

<http://journals.sagepub.com/toc/reab/current>

*Editorial*

### **Editorial: Navigating the ethical terrain of dual use research**

Jan-Hendrik Heinrichs, Serap Ergin Aslan

Open Access Editorial First published April 15, 2025pp. 203–204

This special issue convenes contributions that interrogate the different ethical dimensions of dual use research, a topic increasingly central across disciplines. Traditionally associated with the life sciences and technology, the dual use of research results is now discussed even in areas as abstract as philosophy. This expansion prompts a reconsideration of widely held assumptions about the concept of dual use, moral and institutional responsibility for possible misuse and the scope of research that has dual use potential.

The issue starts with a conceptual article by Hähnel introducing a multidimensional framework for classifying dual use risks. By identifying various factors that render a research output susceptible to misuse, this framework provides a much-needed scaffold for ethical analysis.

Focusing on a national framework, the article by Jacob et al. examines the German approach to managing dual use risks. Emphasizing research freedom coupled with self-regulation, it presents key elements of the process developed by the Joint Committee on the Handling of Security-Relevant Research of German Research Foundation and the German National Academy of Sciences, Leopoldina. Complementing these conceptual and procedural approaches, two contributions wrestle with questions of responsibility and moral accountability...

## **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 19 Apr 2025]

### **Safety, immunogenicity, and effectiveness of chikungunya vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis**

Authors: Mabel Berrueta, Agustín Ciapponi, Agustina Mazzoni, Jamile Ballivian, Ariel Bardach, Juan M. Sambade, Martin Brizuela, Katharina Stegelman, Daniel Comandé, Edward P. K. Parker, Andy Stergachis, Xu Xiong, Flor M. Munoz and Pierre M. Buekens

Content type: Study Protocol 18 April 2025

### **Safety, immunogenicity, efficacy, and effectiveness of Lassa fever vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis**

Authors: Jamile Ballivian, Mabel Berrueta, Agustín Ciapponi, Juan Manuel Sambade, Katharina Stegelmann, Agustina Mazzoni, Ariel Bardach, Martin Brizuela, Daniel Comandé, Noelia Castellana, Edward P. K. Parker, Andy Stergachis, Xu Xiong, Flor M. Munoz and Pierre M. Buekens

## **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

[No new digest content identified]

## **Risk Analysis**

Volume 45, Issue 3 Pages: 473-721 March 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>  
[Reviewed earlier]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>  
[Accessed 19 Apr 2025]  
[No new digest content identified]

### **Royal Society Open Science**

April 2025 Volume 12 Issue 4  
<https://royalsocietypublishing.org/toc/rsos/current>  
[Reviewed earlier]

### **Science**

Volume 388| Issue 6744| 18 Apr 2025  
<https://www.science.org/toc/science/current>  
*Editorial*

#### **When state support for science fails**

BY Antonio Lazcano  
17 Apr 2025: 23

The establishment and growth of scientific communities require long-term planning, political backing, and social and economic support. In many Latin American countries, these entities have been repeatedly shaken by monetary catastrophes, political attacks, and the lack of national and regional developmental strategies that include science and technology. Such volatility has taken its toll on the region's scientific enterprise, because science cannot advance under the vagaries of economic uncertainty, political violence, and unpredictable investment.

In the 1970s, the burgeoning scientific communities of several South American countries, such as Chile, Uruguay, Brazil, and Argentina, were severely damaged by coups d'état that closed universities and sent to prison or into exile hundreds of young scientists and top-level researchers. Reconstruction of academic life has been slow and uneven. Further complicating the ascension of Latin American science is the fact that it is a heterogeneous region in which patches of modernity and wealth coexist with conditions of dismal poverty, and organized crime has made field work dangerous in many localities.

The scientific landscape of Latin America today is still reeling from multiple setbacks. The list includes Argentinian President Javier Milei's decision to drastically reduce science funding; former Brazilian President Jair Bolsonaro's policies that undermined the autonomy of the country's universities and academic research; Nicaraguan President Daniel Ortega's takeover of universities and of the National Academy of Sciences; and the rapidly declining state of science and higher education in Venezuela and Mexico, where the countries' respective leader and former leader, Nicolas Maduro and Andrés Manuel López Obrador, have accused scientists of constituting a nefarious elite engaged in useless research. Political populism, which underlies many of these actions, is a global threat that will not fade away in the near future, and its expansion and radicalization represent major challenges to the scientific enterprise.

Scientists and students have reacted to these assaults with protests and have received considerable support from the independent media and, in Argentina and Mexico, from the National Scientific and Technical Research Council (CONICET) and the National Autonomous University of Mexico (UNAM), respectively. Many Nicaraguans and Venezuelan researchers have had to go into exile but continue to

collaborate from abroad with their colleagues. In countries where governments undermined public health measures intended to control the spread of COVID-19, scientists took matters into their own hands, creating outreach groups that used digital platforms to counter pandemic misinformation. In Brazil, despite Bolsonaro's refusal to acknowledge the damages wrought by deforestation, environmental specialists and citizens alike have continued to speak out in defense of the Amazon rainforest, often at great personal peril.

There is an urgent need to resolve the rift between Latin American governments and scientific communities. In the meantime, there have been some encouraging attempts to forge new collaborations to better support the region's scientific interests. For example, the Mexican National Commission for the Knowledge and use of Biodiversity (CONABIO)—a semiautonomous research center—was, until recent government encroachment, a vital sustainability platform connecting academia, the government, and civil society. Uruguay's National Research and Innovation Agency (ANII) has similarly worked to ensure stable backing for research through a mix of public and private support. And initiatives such as the Amazon Fund, financed largely by Norway and Germany, help insulate Brazilian scientists from domestic political pressures.

The establishment and reinforcement of semi-autonomous research institutions and multinational research networks in the region are a good start, but without sustained support for scientific research, the region will continue to lose talented scientists to countries where faculty positions and funding are more assured. Reversing this course will require the coordinated effort of research institutions, scientific associations, and networks of higher education across Latin America. To do this, these groups will need to leverage the shared history and common cultural backgrounds of the region to develop regional academic strategies that—with international and private support—can diversify funding sources, facilitate the training of the next generation of scientists, strengthen scientific networks, and guarantee scientific freedom.

### **Science and Engineering Ethics**

Volume 31, Issue 2 April 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-2>

[Reviewed earlier]

### **Science Translational Medicine**

Volume 17| Issue 794| 16 Apr 2025

<https://www.science.org/toc/stm/current>

*Viewpoints*

#### **Vaccinology in the artificial intelligence era**

BY Gianmarco Gasperini, Norman Baylor, Steve Black, David E. Bloom, Jakob Cramer, Gaël de Lannoy, Philippe Denoel, Mark Feinberg, Thibault Helleputte, Gagandeep Kang [\[...\]](#) Rino Rappuoli

16 Apr 2025

Artificial intelligence (AI) has already transformed vaccine antigen design and could transform the entire vaccinology pipeline, including immune responses and emerging infectious disease prediction, manufacturing and regulatory processes, clinical trial design and implementation, and vaccine access and equity. However, realizing the promise of AI for vaccinology requires more high-quality data.

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 19 Apr 2025]

[No new digest content identified]



## **Social Science & Medicine**

Volume 370 April 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/370/suppl/C>

[Reviewed earlier]

## **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 19 Apr 2025]

[No new digest content identified]

## **Theoretical Medicine and Bioethics**

Volume 46, Issue 2 April 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-2>

[Reviewed earlier]

## **Travel Medicine and Infectious Diseases**

Volume 64 March–April 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/64/suppl/C>

[Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 30, Issue 3 Pages: i-iv, 143-230 March 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

## **Vaccine**

Volume 52 11 April 2025

<https://www.sciencedirect.com/journal/vaccine/vol/52/suppl/C>

[Reviewed earlier]

## **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 19 Apr 2025]

*Open Access Article*

### **[Evaluating HPV Vaccination Behavior and Willingness to Be Vaccinated and Associated Factors Among University Students in Italy](#)**

by Francesca Licata, Concetta Arianna Scicchitano, Maria Rita Caracciolo and Aida Bianco

Vaccines 2025, 13(4), 426; <https://doi.org/10.3390/vaccines13040426> - 18 Apr 2025

*Abstract*

Objectives: The aim of the present study was to provide insight into potential predictors of HPV vaccination uptake and the willingness to get vaccinated. Methods: This cross-sectional study was conducted among university students using an online, anonymous, self-administered questionnaire. Vaccine hesitancy was measured [...]

*Open Access Review*

### **Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern**

by Ankita Saha, Sounak Ghosh Roy, Richa Dwivedi, Prajna Tripathi, Kamal Kumar, Shashank Manohar Nambiar and Rajiv Pathak

Vaccines 2025, 13(4), 424; <https://doi.org/10.3390/vaccines13040424> - 17 Apr 2025

#### ***Abstract***

Vaccination has been instrumental in curbing the transmission of SARS-CoV-2 and mitigating the severity of clinical manifestations associated with COVID-19. Numerous COVID-19 vaccines have been developed to this effect, including BioNTech-Pfizer and Moderna's mRNA vaccines, as well as adenovirus vector-based vaccines such as [...]

*Open Access Article*

### **Global Status of Adult Immunization Post COVID-19 Pandemic**

by Alba Vilajeliu, Victor Vega, Randie Gibson, Francisco Nogareda, Xiaojun Wang, Donald J. Brooks, Charles Shey Wiysonge, Osman Niyazi Cakmak, Osama Mere, Melanie Marti, Phillip Lambach, Stephanie Shendale, Marcela Contreras, Emmanuel Njambe, Erin Grace Sparrow, Joachim Hombach and Ann Lindstrand

Vaccines 2025, 13(4), 401; <https://doi.org/10.3390/vaccines13040401> - 11 Apr 2025

#### ***Abstract***

Background/Objective: Historically, immunization programs have focused on infants, children, and women of reproductive age. COVID-19 vaccination prompted countries to vaccinate adults. The objective of this manuscript is to provide a global overview of adult immunization policies post COVID-19 pandemic. Methods: We summarized WHO [...]

### **Value in Health**

April 2025 Volume 28 Issue 4 p489-670

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

### **World Development**

Volume 188 April 2025

<https://www.sciencedirect.com/journal/world-development/vol/188/suppl/C>

[Reviewed earlier]

.....  
.....

### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....  
.....

### ***Pre-Print Servers***

arxiv

<https://arxiv.org/>

[Accessed 19 Apr 2025]

[Filters: *Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

arXiv:2504.11910 [pdf, other]

**[The role of wild birds in the global highly pathogenic avian influenza H5 panzootic](#)**

Manon Couty, Claire Guinat, Diletta Fornasiero, François-Xavier Briand, Pierre-Yves Henry, Béatrice Grasland, Loïc Palumbo, Guillaume Le Loc'h

Comments: 2 figures, 1 table, extended data and supplementary data

arXiv:2504.09208 [pdf, html, other]

**[Enhancing U.S. swine farm preparedness for infectious foreign animal diseases with rapid access to biosecurity information](#)**

Christian Fleming, Kelsey Mills, Nicolas Cardenas, Jason A. Galvis, Gustavo Machado

**Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 19 Apr 2025]

[No new digest content identified]

**medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 19 Apr 2025]

[Filter: *All articles*]

**[Herpes zoster vaccination and new diagnoses of dementia: A quasi-randomized study in Australia](#)**

Michael Pomirchy, Christian Bommer, Fabienne Pradella, Felix Michalik, Ruth Peters, Pascal Geldsetzer  
medRxiv 2024.06.27.24309563; doi: <https://doi.org/10.1101/2024.06.27.24309563> Revision

**[Raising the patients voice in influenza research and care with patient-reported outcomes](#)**

Elizabeth Meda-Monzon, Paloma Munoz-Aguirre, Barbara Aida Flores-Aldama, Chad Gwaltney, Jose Bartelt-Hofer

medRxiv 2025.04.15.25325874; doi: <https://doi.org/10.1101/2025.04.15.25325874>

**[Longitudinal Study on Changes in COVID-19 Vaccination Intentions in Benin and Senegal: Insights from Generalized Estimating Equations \(GEE\)](#)**

Ibrahima Gaye, Adama Faye, Valery Ridde, Avahoundje E. Martin

medRxiv 2025.04.16.25325940; doi: <https://doi.org/10.1101/2025.04.16.25325940>

**[Evaluation of rotavirus, pneumococcal conjugate and human papillomavirus vaccination in four Pacific island countries: A cost-effectiveness modelling study](#)**

Natalie Carvalho, Emma Watts, Victoria L. Oliver, Andrew Clark, Murat Ozturk, Siale Akauola, Clare Whelan, Take Naseri, Kylie Jenkins, Inez Mikkelsen-Lopez, Ki Fung Kelvin Lam, Rommel Rabanal, Ross McLeod, Mark Jit, Fiona M Russell

medRxiv 2025.04.14.25325775; doi: <https://doi.org/10.1101/2025.04.14.25325775>

**OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]  
[Website not responding at inquiry]

### **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 19 Apr 2025]

[No new digest content identified]

\*

\*

\*

\*

### **Think Tanks**

#### **Brookings** [to 19 Apr 2025]

<http://www.brookings.edu/>

*Reports, Events*

*No new digest content identified.*

#### **Center for Global Development** [to 19 Apr 2025]

<https://www.cgdev.org/>

*All Research*

*POLICY PAPER*

#### **Unhealthy Subsidies: How Much Do Taxpayers Contribute to Promote Disease?**

William D. Savedoff et al.

April 16, 2025

Health taxes are a well-known fiscal measure for discouraging consumption of unhealthy products like tobacco, alcohol, and sugary beverages. Less well known are opportunities to eliminate government subsidies. This paper is an inquiry into subsidies for tobacco, alcohol, and sugary beverages, produc...

#### **Chatham House** [to 19 Apr 2025]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

#### **Council on Foreign Relations** [to 19 Apr 2025]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

#### **CSIS** [to 19 Apr 2025]

<https://www.csis.org/>

*Reports [Selected]*

#### **What Is Happening to U.S. Humanitarian Assistance? Will the United States Continue to Save Lives?**

Almost 90 days after President Trump's executive order freezing U.S. foreign aid, this paper unpacks the critical losses in emergency response capacity, data, and U.S. credibility, and suggests a path forward for aid reform that minimizes harm.

Report by Michelle Strucke and Marc Cohen — April 18, 2025

**Kaiser Family Foundation** [to 19 Apr 2025]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

*No new digest content identified.*

**McKinsey Global Institute** [to 19 Apr 2025]

<https://www.mckinsey.com/mgi/overview>

*Latest Research*

*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 19 Apr 2025]

<https://odi.org/en/publications/>

*Publications [Selected]*

[Dialogue #2: Using this moment of disruption to transform development cooperation](#)

17 April 2025 *Other*

**Pew Research Center** [to 19 Apr 2025]

<https://www.pewresearch.org/>

*Latest Publications [Selected]*

*No new digest content identified.*

**Rand** [to 19 Apr 2025]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

*No new digest content identified.*

**Urban Institute** [to 19 Apr 2025]

<https://www.urban.org/publications>

[New Research Publications - Selected](#)

**World Economic Forum** [to 19 Apr 2025]

<https://agenda.weforum.org/press/>

*Media [Selected]*

*No new digest content identified.*

.....  
.....

***Public Consultations/Call for Inputs/Call for Papers***

## **ICH - M11 EWG CLINICAL ELECTRONIC STRUCTURED HARMONISED PROTOCOL (CESHARP)**

This topic was endorsed by the ICH Management Committee in November 2018. This new guideline is proposed to provide comprehensive clinical protocol organisation with standardised content, with:

- A Template which presents the format and structure of the protocol, including the table of contents, common headers, and contents;
- A Technical Specification which presents the conformance, cardinality, and other technical attributes that enable the interoperable electronic exchange of protocol content.

The Technical Specification document and Template had reached Step 2b on 27 September 2022 and entered public consultation. They have been updated by the M11 EWG following the comments received. The Technical Specification is now being submitted for a second round of public consultations, and the Template is provided as a support to the consultation.

*Rapporteur:* Dr. Ronald Fitzmartin (FDA, United States)

*Regulatory Chair:* Dr. Noemie Manent (EC, Europe)

Date of *Step 2b*: 13 March 2025 Status: *Step 3*

*Public consultation dates:*

EC, Europe - Deadline for comments by 22 April 2025

HSA, Singapore - Deadline for comments by 25 April 2025

MHLW/PMDA, Japan - Deadline for comments by 1 May 2025

NMPA, China - Deadline for comments by 28 April 2025

SFDA, Saudi Arabia - Deadline for comments by 21 April 2025

TFDA, Chinese Taipei - Deadline for comments by 25 April 2025

\* \* \* \*

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

\* \* \* \*  
\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization,*

*products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*